BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) was the target of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 83,400 shares, a decrease of 19.5% from the November 30th total of 103,600 shares. Currently, 2.2% of the shares of the company are short sold. Based on an average daily volume of 55,000 shares, the days-to-cover ratio is presently 1.5 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a research note on Wednesday, December 18th.

BioCardia Stock Performance

NASDAQ:BCDA traded up $0.04 during mid-day trading on Tuesday, reaching $2.19. The stock had a trading volume of 54,317 shares, compared to its average volume of 267,142. The business has a 50 day simple moving average of $2.23 and a 200 day simple moving average of $2.65. BioCardia has a twelve month low of $1.63 and a twelve month high of $10.79. The firm has a market capitalization of $10.04 million, a price-to-earnings ratio of -0.52 and a beta of 1.25.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.